Learn about cutting-edge science and gain life-enhancing insights.

News

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics…

News

Stephen Bardin to Join atai Life Sciences as CFO Designate

Stephen Bardin to Join atai Life Sciences as CFO Designate June 17, 2022 Stephen Bardin will join as CFO Designate…

Articles

atai Life Sciences to Participate in Upcoming June Healthcare Conferences

NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…

News

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health…

Articles

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a…

Articles

atai Life Sciences to Host Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,…

Press Inquiries

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Headquartered in Berlin, with offices in New York and London, our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life.

GET IN TOUCH
JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit